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Poster Session-I 61transplant, disease status, donor type, absolute neutrophil count, ab-
solute lymphocyte count (ALC), presence of circulating blasts, stem
cell source, CD341 cell dose, conditioning intensity, cytogenetic
profile, antecedent myelodysplastic syndrome (MDS) or secondary
AML, and development of acute graft versus host disease
(GVHD). Deaths attributable to relapse versus non-relapse causes
were recorded for each PFT group.
Results: Pre-transplant characteristics included a median age of
49 yrs (range 7–69 yrs), intermediate/high risk cytogenetics (95%),
CR1/ CR2 (93%), circulating blasts (8%), full intensity conditioning
(78%), related donor (48%), FEV1\ 80% (12%), FVC \ 80%
(15%), and DLCO\ 65% (34%). Diminished FEV1 (\ 80%), dis-
ease status, regimen intensity, ALC, and circulating blasts were asso-
ciated with a significantly reduced disease free survival (Table).
Though FEV1\ 80% and FVC\ 80% were both associated with
a poor DFS (p 5 0.001 and p 5 0.027) and OS (p 5 0.005 and
p5 0.017) by univariate analysis, only FEV1\80% remained asso-
ciated with DFS and OS in the multivariate Cox regression analysis.
Pre-transplant DLCO\ 65% did not reach significance for either
DFS or OS by univariate or multivariate analysis. Relapse related
mortality was more common in patients with a pre-transplant
FEV1 $80% (50%) then patients with an FEV1\80% (39%).
Conclusion: Pre-transplant FEV1\ 80% is associated with re-
duced DFS and OS in patients with AML undergoing allogeneic
HSCT and may provide valuable prognostic information in pre-
transplant evaluations.
Pre-Transplant Factors Associated with Survival
Overall Survival Disease Free SurvivalRisk Factor Risk Ratio p-value Risk Ratio p-valueFEV1$ 80 0.519 0.019 0.467 0.006
Disease Status1 2.144 0.000 1.924 0.004
Regimen Intensity 2 2.174 0.001 2.047 0.003
ALC $ 0.5 0.513 0.003 0.544 0.008
Peripheral Blast 13 - - 2.220 0.0181Disease .CR2 or in relapse.
2reduced intensity conditioning (RIC).
3not associated with overall survival.163
ALLOGENEIC STEM CELL TRANSPLANTION IN RELAPSED/REFRACTORY
ACUTE LEUKEMIA: A LONG TERM SINGLE INSTITUTION EXPERIENCE
Go, A., Stiff, P.J., Parthasarathy, M., Rodriguez, T.E., Smith, S.E.,
Brush, M., Kiley, K., Payan, M., Porter, N., Volle, M., Vesole, D.H.
Loyola University Medical Center, Maywood, IL
Introduction: The clinical outcomes of relapsed and refractory
acute myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL) are dismal in adults treated with conventional therapy. The
majority of patients with relapsed ALL and AML who are subse-
quently cured are transplanted in second remission or, occasionally,
beyond second complete remission. A minority of patients, in the
range of 10 to 20%, with relapsed/refractory disease are cured by
an allogeneic bone marrow transplant.
Objective: We retrospectively examined 137 patients with re-
lapsed and/or refractory acute leukemia who were recipients of allo-
geneic transplants (matched related [MRD], matched unrelated
[MUD] and umbilical cord blood [UCB]) at our center from August
1986 to August 2008 to determine the outcome in advanced leuke-
mia.
Methods: One hundred thirty seven patients (AML, n 5 95 and
ALL, n 5 42) received allogeneic transplants including: 75 MRD,
39MUD, and 23UCB.Conditioning regimens weremostlymyeloa-
blative using combinations of cyclophosphamide(Cy), busulfan (Bu),
etoposide(VP) and total body irradiation (TBI): TBI/Cy/VP, n5 31;
TBI/Cy, n5 66; other TBI based, n5 10; Bu/Cy, n5 20;.other, n5
9. GVHD prophylaxis varied over the years but included a calci-
neurin inhibitor with methotrexate for MUD/MRD transplants
and steroids for UCB transplants.Results:The median age at transplant was 45 years for AML (13–
72) and 32 years for ALL (1–66). Results are shown in the table below
and compared to the survival data (extrapolated) from the NMDP/
CIBMTR database.
Table 1 Transplant Outcomes in Relapsed and/or Refractory
Acute Leukemia
NMDP/ NMDP/N100 day
survival1 year
survival2 year
survivalCIBMTR
-MRDCIBMTR
-MUD1 year–
2year1 year–
2yearAML 95 62% 33% 27%MRD 75 68% 30% 22% 40%–30%MUD 39 54% 30% 26% 30%–20%UCB 23 48% 26% 16%Survival by Age\40yrs 35 74% 48% 38%
40–55yrs 36 56% 29% 26%.55yrs 24 54% 12% 12%ALL 42 57% 21% 11% 35%–20% 30%–15%Conclusion: Our single institutional experience in allogeneic
transplantation for advanced leukemia appears comparable to the
CIBMTR/NMDP database. Younger patients had the best out-
comes. MUD recipients had comparable outcomes to MRD. There-
fore, we recommend that younger patients with advanced leukemia
be strongly considered for allogeneic transplant, regardless of stem
cell source, as the only potentially curative option.164
SELECTIVE REPROGRAMMING OF CD19-SPECIFIC T CELLS WITH IL-21
AND CD28 SIGNALING FOR ADOPTIVE IMMUNOTHERAPY OF ACUTE
LYMPHOBLASTIC LEUKEMIA
Singh, H.1, Huls, M.H.1, Dawson, M.J.1, Mi, T.1, Lee, D.A.1,
Kebriaei, P.2, Shpall, E.J.2, Hackett, P.B.3, June, C.H.4,
Champlin, R.E.2, Cooper, L.J.N.1 1U.T. M.D. Anderson Cancer Center,
Houston, TX; 2U.T.M.D. Anderson Cancer Center, Houston, TX; 3Uni-
versity of Minnesota, St Paul, MN; 4University of Pennsylvania Cancer
Center, Philadelphia, PA
Adoptive transfer of T cells has been used to treat and prevent ma-
lignancies and opportunistic infections. To improve therapuetic effi-
cacy, investigators initially redirected specificity through the
introduction of immunoreceptors. Early-phase trials are now under-
way to demonstrate the safety and feasibility ofCD19-specific chime-
ric antigen receptors (CARs)which recognize antigen independent of
MHC. However, it is recognized that improving in vivo persistence
will be needed to enhance therapeutic potential of CAR1 T cells.
To this end we developed two approaches: (i) intrinsic: altering the
signalling pathway of T cells to improve persistence and (ii) extrinsic:
altering the culturing milieu to numerically expand CAR1 T cells
with a proliferative advantage. Previously we reported on a 2nd gen-
eration CAR (designated CD19RCD28) which activates T cells
through CD3-z and CD28 endodomains, to sustain proliferation of
CD19-specific T cells. One extrinsic factor to be assessed is IL-21,
a member of the common g-chain receptor cytokine family that can
signal CD81T cells in conjunction with CD28 to support prolifera-
tion and acquisition of desired effector functions.Wenow report that
the addition of exogenous IL-21 favors the microenvironment to se-
lectively propagate CAR1 CD81 T cells with ability to kill CD191
tumor targets. To evaluate this role for IL-21, peripheral blood-de-
rived T cells were electroporated with CD19RCD28 CAR expressed
as a Sleeping Beauty (SB) transposon and propagated in the presence of
IL-2 and/or IL-21 on g-irradiated CD191 artificial antigen present-
ing cells (aAPC). There was a selective outgrowth of CAR1CD81T
cells when IL-21 was present in the culture medium, compared with
predominant outgrowth of CAR1CD41T cells when IL-21 was ab-
sent (Table).The propagatedCAR1Tcells producedmore IFN-g in
response toCD191 stimulator cells compared to cells cultured in par-
allel only on IL-2, and displayed a centralmemory surface phenotype
while retaining an ability to exhibit CD19-dependent cytolysis.
62 Poster Session-IThese data demonstrate that a combination of intrinsic and extrinsic
approaches can be used to shape a population of CAR1 T cells that
exhibit redirected specificity for CD19. Since the SB system has
achieved regulatory approval and the aAPC are being manufactured
to clinical grade through PACT/NHLBI, investigators are now
able to infuse cytolytic CD81 and CD41 T cells expressing markers
of central memory and ability to sustain proliferation.
Expression of CAR on CD81and CD41 T cells propagated on
aAPC with IL-2 1/- IL-21
Culture conditions CD41CAR1 CD81CAR1IL-2 42% 1%
IL-2 1 IL-21 22% 76%165
THE INTERACTION BETWEEN LEUKEMIA AND BONE MARROW STROMA
PROTECTS THE TUMOR CELLS FROM CHEMOTHERAPY- AND RADIO-
THERAPY-INDUCED APOPTOSIS
Barriga, F.2, Riquelme, E.2, Macanas, P.1, Besa, P.1, Broekhuizen, R.1,
DiPersio, J.F.3, Kalergis, A.2, Nervi, B.1 1Pontificia Universidad Catolica
de Chile, Santiago, Chile; 2Pontificia Universidad Catolica de Chile, San-
tiago, Chile; 3Washington University School of Medicine, Saint Louis,
Chile
Introduction: The tumor microenvironment is increasingly be-
ing recognized as a critical factor in mediating cancer development
and drug resistance. Despite a high response rate to chemotherapy,
the vast majority of patients with AML are destined to relapse due
to residual disease in the bone marrow (BM). We have previously
reported that AMD3100 (CXCR4 inhibitor) produces a rapid and
transient leukemia cell mobilization from BM into peripheral
blood, sensitizing leukemia cells to chemotherapy (ASH 2006,
Nervi et al).
Objectives:To evaluate the effect of the interaction between APL
and BM stroma in the expansion, survival and chemo/radio sensitiza-
tion of leukemia cells.
Results:We used amouse leukemia cell line generated by knock-
ing in the human PML-RARa cDNA (APL). To evaluate the phys-
ical interaction between APL cells and the bone marrow stromal
cells (BMSC), 5104 APL cells were cultured for 24h without or
with a BMSC monolayer (M2-10B4), or fibroblast monolayer (L-
cell). We observed 0%, 80% and 15% respectively (p\0.001). To
investigate the chemo/radio-sensitivity of APL cells, the latter
were cultured without and with BMSCs for 24h followed by the
addition of various increasing concentrations of AraC for 24h or ra-
diotherapy (xRt). Flow cytometric analysis of GR11 cells using ap-
optotic indicators such as Bcl-2, Annexin V and caspase-3 revealed
a significant protection from cell death of the APL cells by the BM
stroma. Furthermore, the analysis of the proliferative state of these
APL cells with or without stroma by flow cytometry using BrDU,
CFSE and PI showed a decreased cellular proliferation of APL cells
in the presence of BM stroma (7% proliferates with stroma versus
70% without stroma). N 5 24 mice were injected with 106 APL
cells iv and after 14 days the mice had an average of 10% APL cells
in the peripheral blood. Eight mice received 300cGy xRt in day 16,
and 8 mice received the combination of 300cGy 1 AMD3100 (1h
before and 3h later xRt to interrupt APL/stroma interaction). As
a control group 8 mice were left untreated. The mean survival for
the untreated, xRt, and xRt1AMDwere 21, 26 and 29 days respec-
tively (p\0,02).
Conclusion: BMmicroenvironment recruits APL cells to G0 and
increases antiapoptotic signals that protects leukemia cells from
apoptosis mediated by cytotoxic agents. The interruption of this
interaction may improve outcomes in leukemia therapy.166
OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR PA-
TIENTS WITH ACUTE LEUKEMIA TRANSFORMED FROM MYELOFIBROSIS
Ciurea, S.O., de Lima, M., Giralt, S., Alousi, A., Kebriaei, P.,
Khouri, I.F., Anderlini, P., Andersson, B.S., Hosing, C.M.,
Champlin, R.E., Popat, U. University of Texas MD Anderson Cancer
Center, Houston, TXBackground and Rationale: Transformation of myelofibrosis
(MF) to acute leukemia (.20% blasts) portends a grave prognosis. Al-
logeneic stem cell transplantation (ASCT) is a curative approach for
patients with acute leukemia; however, the outcomes of ASCT in pa-
tients withMF transformed to acute leukemia are currently unknown.
Methods: Fifty-one consecutive patients with either primary
(PMF) or secondary (SMF) were transplanted at UTMDACC after
1994. Thirteen patients who developed AML (25%), 10 arising from
PMF and 3 with SMF, received an ASCT from a sibling or matched
unrelated donor. Median age was 59 years. Five patients (38%) had
prior splenectomy. JAK2V617F mutation analysis was performed in
7, and was present in 5 patients. Cytogenetics were intermediate in
10 and poor-risk in 3 patients. Seven patients (54%) were not in remis-
sion at the time of transplant. Eleven of 13 patients received induction
chemotherapy; 6 achieved remission, while 7 had persistent disease at
the time of transplant. One patient had a prior autologous transplant
and 2 patients had prior allogeneic transplant for myelofibrosis. The
donors were matched siblings (7 patients), matched unrelated (4 pa-
tients) and 1 antigen mismatched relatives (2 patients). The stem cell
source was peripheral blood in 9 and bone marrow in 4 patients.
Nine patients received a reduced-intensity conditioning regimen
with a fludrabine-melphalan-based regimen, and 4 myeloablative
conditioning (3 fludarabine-busulfan, 1 busulfan-cyclophosphamide).
Results: All patients engrafted, 75% achieved full donor chime-
rism, on day 30. Neutrophil and platelet engraftment occurred after
a median of 13 and 21.5 days. Twelve evaluable patients achieved re-
mission; 3 subsequently relapsed. JAK2V617F mutation became
negative after transplant in all tested patients and reappeared in 1 pa-
tient who later relapsed. Grade 2–4 aGVHD developed in 3 patients
(grade 3–4 in one) and cGVHD in 4/11 evaluable patients (extensive
in two). After a median follow-up of 17.2 months (range 7.2–128.6
mo), OS and EFS were 49% (SE 15%) and 44% (SE 14%), respec-
tively. Six patients died, related to disease relapse (2), pneumonia (2),
GVHD (1), and hepatic failure (1).
Conclusion: Patients with acute leukemia transformed from my-
elofibrosis with good performance status can achieve durable com-
plete remissions with ASCT.167
TOLERABILITY AND OUTCOMES OF A TARGETED INTRAVENOUS BUSUL-
FAN AND FLUDARABINE (T-BU/FLU) CONDITIONING REGIMEN FOR THE
TREATMENT DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA (AML)
Fernandez, H.F., Perkins, J., Field, T., Alsina, M., Ayala, E., Kharfan-
Dabaja,M., Ochoa, J.L., Perez, L., Raychaudhuri, J., Anasetti, C.Moffitt
Cancer Center, Tampa, FL
In an effort to reduce non-relapse mortality (NRM) and improve
survival in patients with AMLwe evaluated targeting busulfan to daily
AUCof 5300mmol/min/day. Since 2004we have treated 100 patients,
with de novo (66%) or secondary AML (34%), with a median age of 48
years (range 21–68)with a targeted IVbusulfan plus fludarabine (t-Bu/
Flu) reduced intensity regimen. 52 patients were in CR1, 23 in CR2
and 25 inadvanced AML. Of those in CR1, 50% had intermediate-
risk cytogenetics (IRC) and 50% had unfavorable-risk cytogenetics
(URC) at diagnosis. The patients were treated with t-BuFlu (Bu:
130–145 mg/m2/day on days 1 and 2 with pharmacokinetic targeting
for days 3 and 4; Flu 40mg/m2/day for 4 days). A median Bu AUC of
5265mmol/min/day was achieved. Patients received matched sibling
(38%), unrelated (40%), mismatched unrelated (21%) or mismatched
related (1%) HCT. GVHD prophylaxis consisted of tacrolimus plus
methotrexate or mycophenolate mofetil. Mismatched recipients re-
ceived rabbit ATG 7.5mg/kg as additional GVHD prophylaxis.
Results: NRM was 5% at 100 days and 17% at 1 year. Relapse
rates for patients in CR1 were 38.5 and 42.3 % (p 5 ns) for the
IRC and URC, respectively. With a median follow-up of 1 year,
EFS was 54% and OS was 57% at 1 year. There was a lower EFS
(63 vs. 30%, p 5 0.04) and a trend towards better OS (64 vs. 46%,
p5 0.07) for patient transplanted in CR1 compared to those beyond
first CR. There was no difference in the outcomes in EFS (p5 0.56)
or OS (p 5 0.98) between the IRC (n 5 56) and URC groups (n 5
40). Patients in first or second remission (n 5 74) had a better OS
(62 vs. 40%, p 5 0.04) than those not in remission (n 5 26) at the
time transplant. We noted a slight difference in outcomes based on
age below (n 5 66) or above (n 5 34) 55 years, but neither reached
statistical significance (EFS 58 vs. 44%, p 5 0.17; OS 60 vs. 49%,
